2021 · Wang et al. — Response to: Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19
Super-Abstract
This is a response letter to a commentary proposing hydrogen therapy in COVID-19, published in the same journal issue. No abstract is available for this letter. It represents part of an academic exchange on the theoretical rationale for H₂ in COVID-19 management. (QJM: Monthly Journal of the Association of Physicians, 2021.)
Commentary
This short response letter (no abstract available) is the rejoinder to PMID 33151329, which proposed H₂ therapy as an adjuvant COVID-19 treatment. Response letters in clinical journals typically clarify, add nuance, or raise objections to the original proposal. Without access to the full text, the specific content of this response — whether supportive or critical — cannot be summarized here. Both letters together reflect the scientific community beginning to discuss the potential of H₂ therapy in acute respiratory infections around 2020–2021. For the full argument, please refer to DOI: 10.1093/qjmed/hcaa302.
Key quotes
- „Response to: Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19.“ — title as the only citable text — no abstract available
Our assessment
This is a response letter without available abstract. No experimental data are included. It cannot serve as standalone evidence for or against H₂ therapy in COVID-19. It is best understood as part of an academic debate; the original commentary (PMID 33151329) and this response should be read together via their respective DOIs.
Study design
- Type: response letter / theoretical commentary · n: n/a · H₂ delivery: unspecified
- Result: no experimental data — abstract not available in indexed record
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.